BioSpace News Archive

Juvenescence Closes on Series A Financing Worth $50 Million to Focus on Human Longevity

Juvenescence closed on an oversubscribed Series A financing worth $50 million. It brings the company’s total fundraising to $63 million.The company is focused on developing therapies to increase healthy human longevity.

June 12, 2018
·
2 min read
·
Mark Terry
Policy

AbbVie Responds to FDA Criticism Over Manufacturing Complaints

The U.S. Food and Drug Administration (FDA) recently reprimanded AbbVie for its processes for investigating reports of deaths associated with three of its drugs.

June 12, 2018
·
2 min read
·
Mark Terry
Business

Novartis Pays Regenxbio $100 Million for Gene Therapy Technology Under AveXis License Agreement

Regenxbio snagged $100 million from Novartis under its license agreement with gene-therapy company AveXis, which the Swiss company acquired for $8.7 billion earlier this year.

June 12, 2018
·
2 min read
·
Alex Keown
BioCapital

First International NASH Day is a Call to Action

The prevalence of nonalcoholic steatohepatitis (NASH) is increasing across the globe and is expected to be the leading indication for liver transplants by 2020. Despite that, awareness of the disease is somewhat low.

June 12, 2018
·
2 min read
·
Alex Keown
Business

Another High Profile Departure at GSK as Vaccines Head Luc Debruyne Plans to Leave the Company

More management changes are happening at GlaxoSmithKline. This morning the company said longtime senior executive Luc Debruyne is stepping down from his role at the end of the year.

June 12, 2018
·
2 min read
·
Alex Keown
Drug Development

Eli Lilly and AstraZeneca Abandon Alzheimer’s Drug

Yet another drug for Alzheimer’s has been tossed in the trash. AstraZeneca and Eli Lilly announced they have abandoned two late-stage clinical trials of lanabecestat for Alzheimer’s disease.

June 12, 2018
·
3 min read
·
Mark Terry
Drug Development

FDA Grants Rare Pediatric Disease Designation to Albireo’s Liver Disease Drug

The U.S. Food and Drug Administration (FDA) granted Boston-based Albireo Pharma’s A4250 rare pediatric disease designation.

June 12, 2018
·
2 min read
·
Mark Terry
Drug Development

FDA Provides Expedited Path Forward For Sage’s Depression Treatment SAGE-217

Following a meeting with the U.S. Food and Drug Administration Sage Therapeutics is seeing the goal line for potential expedited approval of its major depressive disorder (MDD) and postpartum depression (PPD) treatment, SAGE-217.

June 12, 2018
·
2 min read
·
Alex Keown
Business

E-Scape Bio Obtains Worldwide Rights from AbbVie for Selective S1P5 Program Targeting CNS-related Lysosomal Storage Disorders

E-Scape adds late pre-clinical program to pipeline of genetically defined programs to treat CNS disorders. AbbVie will become an investor in E-Scape.

June 12, 2018
·
3 min read
Biotech Beach

Veterans Connect, Learn Creative Painting with Wounded Warrior Project

Injured veterans and their guests connected with other warriors and learned how to create their own masterpieces with the help of an experienced painter during a Wounded Warrior Project® (WWP) event.

June 12, 2018
·
2 min read